Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease.
Sign Up to like & getrecommendations! Published in 2021 at "Biomedical reports"
DOI: 10.3892/br.2021.1408
Abstract: Vonoprazan, a novel potassium-competitive acid blocker, results in greater inhibition of gastric acid secretion than proton pump inhibitors (PPI). The aim of this study was to assess the long-term outcomes of patients with PPI-resistant gastroesophageal… read more here.
Keywords: vonoprazan therapy; erosive group; group; non erosive ... See more keywords